Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Court Invalidates Zegerid Patents; Adding more Visibility and Certainty to a Key Pipeline Opportunity
Tweet Send to a Friend
Needham & Company maintains a 'Strong Buy' rating on Par Pharmaceutical (NYSE: PRX), price target $29.
Needham analyst says, "A ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "A ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
